
Jan 8 (Reuters) - CytomX Therapeutics Inc CTMX.O:
CYTOMX THERAPEUTICS ANNOUNCES BUSINESS UPDATE AND COMPANY MILESTONES FOR 2026
CYTOMX THERAPEUTICS INC - CX-2051 PHASE 1 DATA ON TRACK FOR Q1 2026
CYTOMX THERAPEUTICS: INITIAL CX-801 PHASE 1 COMBINATION DATA WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA EXPECTED BY END OF 2026
CYTOMX THERAPEUTICS INC - VARSETA-M PHASE 1 STUDY TO START IN Q1 2026